As natural biopolymers, hydrolyzed collagens
are derived from a group of molecules of different sizes and lengths that can be described by two chief characteristics: average molecular weight and molecular weight distribution.
In addition to collagens
, proline hydroxylation probably affects interaction of many more cellular proteins, because 4-hydroxyproline residues are ubiquitous in proteins with collagen
-like domains (Myllyharju and Kivirikko 2004).
Interferon gamma inhibits the activity of fibroblasts in the cutaneous and subcutaneous regions and thereby decreases the synthesis of collagen
II, and TGF-[[beta].
FibroGen's recombinant collagens
and gelatins address several promising market opportunities.
One potential drawback with collagens
is that they are bovine-derived, and some patients are hypersensitive to bovine products.
The report provides analysis and review of the key clinical trials being carried out globally and across key Collagens
market categories - Collagens
Spondyloepiphyseal dysplasia (SED) is a rare, type II collagen
disorder that is defined and diagnosed by its characteristic clinical and radiologic features.
Ala-Kokko and her colleagues have now linked a defect in a collagen
gene to herniated disks, an excruciatingly painful back problem that afflicts many people.
ArteFill contains precision-filtered PMMA microspheres suspended in ultra-purified collagen
and will be manufactured in the United States in accordance with rigorous FDA quality requirements.
INAMED Corporation (Nasdaq:IMDC), a global healthcare company and the industry leader in the popular dermal filler market, today announced that Spain's Ministry of Health has granted approval for Inamed to begin distribution and marketing of its CosmoDerm(R) and CosmoPlast(R) human collagen
products, which require no pre-treatment skin test.
is a privately held biotechnology company focused on the discovery, development, and commercialization of therapeutics, recombinant human collagens
, and recombinant gelatins to address unmet needs in the medical, pharmaceutical, and consumer markets.
FibroGen's recombinant gelatins are unique materials, and are produced through the application of FibroGen's proprietary technology for the production of collagens
and related materials in recombinant systems such as yeast.
Additionally, FibroGen has over 20 active agreements with leading pharmaceutical and medical device manufacturers for development or feasibility testing of the Company's recombinant human collagens
or gelatin as replacement components for animal-sourced materials within in-market and R&D stage products.
The success of this financing allows FibroGen the opportunity to aggressively expand activities manufacturing scale up and commercialization of our synthetic collagens
and gelatin and to accelerate the research and development efforts aimed toward scarring, fibrosis, and fibroproliferative cancers," said FibroGen's Chief Executive Officer, Thomas B.
is exploiting its expertise and intellectual property by creating a business model driven by the near-term market introduction of recombinant collagens
and gelatins with longer-term drug development programs addressing major unmet medical needs in dermal scarring, deep organ fibrosis and tissue regeneration.